The Italian Competition Authority initiates a proceeding against the sale of a generic drug for the treatment of HIV infections sold as a remedy to fight the COVID-19 virus (Kaletra)

1.Introduction The spread of the Covid-19 pandemic is unfortunately accompanied by the equally rapid one of unfair commercial practices in Italy. A worrying scenario, also for potential, serious effects on people’s health, on which the Italian Competition Authority (‘ICA’) continues to keep the spotlight on, initiating proceedings against many online platforms, from the largest to the smallest, whenever it deems it necessary. The attempts to extort money from consumers, relying on the anxiety and fear related to the contagion from Covid-19, are in fact many and do not spare any commercial genre: detergents, cosmetics, supplements, fundraisers, “miraculous” drugs, everything lends itself to swindle consumers, relying on fears generated by the ongoing epidemic. In this context, ICA’s

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.